Barr signs agreements to settle Mirapex and Aggrenox patent challenges (Pharmaceutical Business Review)

Barr signs agreements to settle Mirapex and Aggrenox patent challenges (Pharmaceutical Business Review)
Barr Pharmaceuticals has announced that its Barr Laboratories subsidiary has signed a settlement agreement and a license agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheims Mirapex product.